HOME >> BIOLOGY >> NEWS
Molecular marker predicts success of breast cancer treatment

A new study demonstrates that the ratio of the expression levels of two genes can be used to accurately predict the clinical outcome of tamoxifen treatment for early stage breast cancer. It is the first method to reliably differentiate between patients who experienced disease-free survival and those at risk for tumor recurrence. The findings also provide new insight into the molecular mechanisms that may contribute to tamoxifen resistance.

Tamoxifen is one of the most widely used therapies for breast cancer. It works by blocking the action of estrogen on breast cancer cells. Estrogen directs the growth of normal breast cells, but can also stimulate the abnormal and unregulated cell growth associated with breast cancer. Unfortunately, nearly 40% of breast cancer patients fail to respond to tamoxifen or eventually become resistant to treatment, and there is no reliable way to predict treatment outcome. Dr. Dennis C. Sgroi from the Pathology Department at Massachusetts General Hospital and Dr. Mark G. Erlander from Arcturus Bioscience, Inc. in Mountain View, California examined the gene expression levels in 60 breast cancers from patients who were treated with tamoxifen after their surgery. Measuring gene expression is a way to examine whether or not a gene is functioning. They discovered that the ratio of the expression levels of two genes, HOXB13 and IL17BR, accurately predicted whether tumors reoccurred after treatment with tamoxifen. The researchers also found that when HOXB13 levels were experimentally elevated in cells from normal breast tissue cultured in the laboratory, the cells showed obvious morphological changes and became more invasive in response to growth signals. "This suggests that HOXB13 may directly contribute to tumor invasion and metastasis," explains Dr. Sgroi.

The researchers conclude that the HOXB13:IL17BR expression ratio may provide an effective molecular marker for identifying breast cancer patients who will be less likely to
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
3-Jun-2004


Page: 1 2

Related biology news :

1. Molecular motor implicated in tissue remodeling
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Molecular staples shape a cancer killer
5. Molecular motor myosin VI moves hand over hand, researchers say
6. Molecular therapeutics advance fight against brain cancer
7. Molecular motor shuttles key protein in response to light
8. Molecular traffic cop directs cellular signals
9. Molecular image of genotoxin reveals how bacteria damage human DNA
10. Molecular mechanism found that may improve ability of stem cells to fight disease
11. Molecular midwives hold clues to the origin of life

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/13/2018)... ... November 13, 2018 , ... ... systems for controlled-environment cultivation applications. VYPR 2 is well suited for sole-source and ... and ornamental growing markets. , “As an all-purpose light which can be ...
(Date:11/13/2018)... , ... November 12, 2018 , ... Board-certified periodontist Dr. ... welcoming individuals with multiple missing teeth in Santa Ana, CA and surrounding areas, who ... day. Using decades of experience, Dr. Kim regularly helps patients get the advantages that ...
(Date:11/9/2018)... Pa. (PRWEB) , ... November 08, 2018 , ... ... with advanced touch screen control. Heating blocks, also known as dry bath incubators ... variety of tubes and containers. , For the new heating blocks, Boekel ...
Breaking Biology News(10 mins):
(Date:11/5/2018)... ... November 05, 2018 , ... ... company backed by Siemens Healthineers and several healthcare VC firms announces at Distributed ... and making a history by purchasing tokens and obtaining its first radiology interpretations, ...
(Date:11/3/2018)... ... November 01, 2018 , ... Come to ... Jean Mulinde, Senior Advisor, Division of Clinical Compliance Evaluation, CDER, FDA will be ... data reliability. , What should clinical research industry stakeholders keep in mind when ...
(Date:10/31/2018)... ... October 30, 2018 , ... Myoscience, Inc. announced today ... Clinic in Memphis, Tennessee. This study enrolled 125 patients and compares the ... managing pain after total knee replacement surgery (TKA). , The Myoscience iovera° system ...
(Date:10/31/2018)... ... October 30, 2018 , ... Today, the National Corn Growers Association (NCGA) announced ... competition is to find new and innovative uses of field corn. NineSigma is serving ... billion bushels of corn and are on pace to produce the second largest crop ...
Breaking Biology Technology:
Cached News: